Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.